GONADOTROPIN-RELEASING HORMONE ACTION
促性腺激素释放激素作用
基本信息
- 批准号:7561851
- 负责人:
- 金额:$ 7.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-05-01 至 2008-04-30
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAgonistBreast CarcinomaCharacteristicsClinicalComputer Retrieval of Information on Scientific Projects DatabaseConditionCryptorchidismDatabasesEnd PointFemaleFibroid TumorFundingGonadotropin Hormone Releasing HormoneGonadotropin-Releasing Hormone AnalogGonadotropin-Releasing Hormone ReceptorGrantHormonesInstitutionLeadLegal patentLiteratureModelingNeurosecretory SystemsOvarianOvaryPeptidesPerimenopausePharmaceutical PreparationsPhysiologicalPolycystic Ovary SyndromePrecocious PubertyPrimatesProstaticReproductionResearchResearch PersonnelResourcesRoleSiteSourceStructureTestisTherapeuticTherapeutic InterventionTimeUnited States National Institutes of Healthanalogbasebirth controlchemotherapyendometriosisgenetic regulatory proteinimprovedmalepromoterreceptorreceptor couplingstoichiometry
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Since isolation of gonadotropin-releasing hormone (GnRH) in the early 1970s, basic and clinical discoveries have presented uses for GnRH analogs. Among these are treatments for endometriosis/fibroids, polycystic ovary disease, perimenopause, protection of the ovary and testes (i.e., during chemotherapy), assisted reproduction, precocious puberty, male and female birth control, prostatic, ovarian and mammary carcinomas, cryptorchidism, and other conditions. Studies of GnRH action have provided a great deal of useful, basic information to the field of neuroendocrine peptides. In addition, nearly 10,000 biologically active GnRH analogs are now described in the scientific and patent literature, providing an exquisite database for understanding structure-activity relations; these analogs include well-defined full agonists and full antagonists, many of which are metabolically stable or have other desirable characteristics. Improved understanding of the mechanism of action of this hormone will likely lead to opportunities for improved drugs (i.e., fewer side effects, orally active and cheaper) and more specific therapies. "Non-traditional" approaches also have potential; approaches involving some of these are described in the present proposal. The specific aims of this study will advance both our basic understanding and will identify new sites and approaches potentially amenable to therapeutic intervention. These include: I. Stoichiometry and role of GnRH receptor-receptor interactions; II. GnRH receptor coupling to effectors and other regulatory proteins; III. Real-time dynamic examination of GnRH-stimulated promoter expression; IV. Therapeutic approaches based on partial agonism; V. Physiological endpoints in a primate model.
这个子项目是众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
P. MICHAEL CONN其他文献
P. MICHAEL CONN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('P. MICHAEL CONN', 18)}}的其他基金
High Throughput Screening for Pharmacoperones of the V2 Receptor
V2 受体药用酮的高通量筛选
- 批准号:
8696856 - 财政年份:2013
- 资助金额:
$ 7.59万 - 项目类别:
High Throughput Screening for Pharmacoperones of the V2 Receptor
V2 受体药用酮的高通量筛选
- 批准号:
8555110 - 财政年份:2013
- 资助金额:
$ 7.59万 - 项目类别:
High Throughput Screening for Pharmacoperones of the V2 Receptor
V2 受体药用酮的高通量筛选
- 批准号:
8816998 - 财政年份:2013
- 资助金额:
$ 7.59万 - 项目类别:
HIGH THROUGHPUT SCREENING ASSAY DEVELOPMENT FOR PHARMACOPERONES
制药公司的高通量筛选检测方法开发
- 批准号:
8357845 - 财政年份:2011
- 资助金额:
$ 7.59万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 7.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 7.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 7.59万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 7.59万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 7.59万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 7.59万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 7.59万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 7.59万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 7.59万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 7.59万 - 项目类别:














{{item.name}}会员




